PC
NTLA icon

Paulson & Co’s Intellia Therapeutics NTLA Stock Holding History

Paulson & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-48,600
Closed -$778K – 76
2017
Q2 		$778K Sell
48,600
-30,000
-38% -$419K 0.01% 103
2017
Q1 		$1.11M Buy
+78,600
New +$1.05M 0.01% 91

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Paulson & Co's NTLA Position: Q3 2017 in Review

Paulson & Co sold out of Intellia Therapeutics (NTLA) in Q3 2017, closing a stake of 48,600 shares — an estimated $778K sold.

Paulson & Co first reported a position in NTLA in Q1 2017 and held it in 2 quarters. The position peaked at $1.11M in Q1 2017. 85 funds tracked by Wall St. Rank hold NTLA as of Q3 2017.

  • Paulson & Co reported no remaining Intellia Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Paulson & Co sold 48,600 Intellia Therapeutics shares in Q3 2017, an estimated $778K.
  • Paulson & Co first reported a position in Intellia Therapeutics in Q1 2017 and held it in 2 quarters.
  • Paulson & Co's Intellia Therapeutics position peaked at $1.11M in Q1 2017.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.